Literature DB >> 1423308

Deletion of chromosome 11p13-11p15.5 sequences in invasive human ovarian cancer is a subclonal progression factor.

B Vandamme1, W Lissens, K Amfo, P De Sutter, C Bourgain, E Vamos, J De Grève.   

Abstract

In human ovarian cancer, multiple specific chromosomal deletions can be found by cytogenetic analysis or molecular techniques such as restriction fragment length polymorphism probing. This work confirms the loss of HRAS alleles in 1 out of 2 cases of invasive ovarian cancer as determined in 32 samples or cell lines derived from 19 patients. Results with other polymorphic probes indicate that a consensus deletion probably includes 11p15.5-11p13. Tumor suppressor genes might be located in the deleted area, and deletion of the gene might then play a role in disease progression. Examination of DNA from distinct tumor sites of individual patients indicates clonal heterogeneity in the malignant cell population, indicating that loss of 11p sequences is a late event in the disease progression. Loss of alternate 11p alleles at different disease sites in one patient is inconsistent with the current model of tumor suppressor gene inactivation. The 11p deletion seems to be limited to ovarian cancers in younger patients. Eight novel permanent ovarian cancer cell lines, previously not described in the literature and derived from tumor sites from five patients, were included in the current analysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423308

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  A 7.5 Mb sequence-ready PAC contig and gene expression map of human chromosome 11p13-p14.1.

Authors:  B Gawin; A Niederführ; N Schumacher; H Hummerich; P F Little; M Gessler
Journal:  Genome Res       Date:  1999-11       Impact factor: 9.043

Review 2.  Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.

Authors:  Patriciu Achimas-Cadariu; Paul Kubelac; Alexandru Irimie; Ioana Berindan-Neagoe; Frank Rühli
Journal:  J Ovarian Res       Date:  2022-06-03       Impact factor: 5.506

3.  Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma.

Authors:  R Shipman; P Schraml; M Colombi; G Raefle; C U Ludwig
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

4.  Monoallelic expression of the insulin-like growth factor-2 gene in ovarian cancer.

Authors:  K Yun; M Fukumoto; Y Jinno
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

5.  Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors.

Authors:  G Chenevix-Trench; J Kerr; M Friedlander; T Hurst; B Sanderson; M Coglan; B Ward; J Leary; S K Khoo
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

Review 6.  The genetic analysis of ovarian cancer.

Authors:  A N Shelling; I E Cooke; T S Ganesan
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

7.  Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.

Authors:  Joanna Vermeij; Erik Teugels; Claire Bourgain; Ji Xiangming; Peter in 't Veld; Vanessa Ghislain; Bart Neyns; Jacques De Grève
Journal:  BMC Cancer       Date:  2008-01-08       Impact factor: 4.430

8.  Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.

Authors:  H Gabra; L Taylor; B B Cohen; A Lessels; D M Eccles; R C Leonard; J F Smyth; C M Steel
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

9.  Characterisation of seven human ovarian tumour cell lines.

Authors:  A P Wilson; M Dent; T Pejovic; L Hubbold; H Radford
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.